Urologic cancer burden has globally increased amid population growth and aging. Routine use of advanced imaging modalities has increased the early detection of these tumors, and together with technological advances in radiotherapy planning and delivery techniques (stereotactic ablative body radiotherapy/radiosurgery) have made it possible effective radiation treatments with a relatively low toxicity profile in the primary tumor and selected cases of metastatic setting.
Nevertheless, robot-assisted surgery has allowed numerous potential benefits to the patients, reduced hospital stay and minor risk of infection and postoperative complications than conventional surgery.
The real-time molecular characterization of cancer disease, with the advent of potentially curative target therapies, has also becoming crucial to optimize a patient-tailored therapeutic approach based on tumor aggressiveness and clonal evolution.
In this scenario, a multidisciplinary team approach including all the specialties involved in the diagnostic and therapeutic procedures represents the key to offer personalized treatment plans and quality cancer care.
Recent advances in the diagnosis and treatment of prostate, bladder and kidney cancers, even in the setting of oligorecurrent/oligometastatic disease, have led to a growing evidence of improved control of disease and survival, which needs to also focus on treatment-related quality of life.
Given the current trend towards the hyperspecialized combination of diagnostics and therapeutics, both molecular and clinical data are desirable. We propose to create a multidisciplinary collector of scientific evidence that strengthen communication and synergy among the disciplines involved in an Uro-oncology molecular tumor board (Urology, Radiation Oncology, Clinical Oncology, Radiology, Nuclear Medicine, Pathology, Molecular Biology).
The Research Topic will cover technological advances in the field of prostate cancer, urothelial and renal tumors, regarding:
• next-generation imaging (multiparametric/whole body magnetic resonance, positron emission tomography, prostate cancer cell-ligands)
• the possible role of molecular biomarkers and/or genomic profiling
• surgical techniques
• radiation therapy, conventional chemotherapy and targeted therapy (monoclonal antibodies including PARP-inhibitors, immune modulation, androgen receptor signaling inhibitors)
• radiometabolic approaches
• efficacy and safety of combinatorial strategies
• advances in the management of treatment-related side effects (i.e. urinary incontinence/obstruction, radiation-induced proctitis, erectile disfunction, bladder shrinking, immune-related adverse events)
• features to evaluate and/or improve tumor detection and treatment response; treatment-related quality of life, patient-reported outcomes (PROs) and patient-reported outcome measures (PROMs); quality of care and cost-effectiveness of molecular tumor board.
Systematic and narrative reviews, metanalysis, prospective observational studies, retrospective series, subgroup analysis, real-world experiences, cost-effective analysis, clinical and pre-clinical data will be evaluated.
Urologic cancer burden has globally increased amid population growth and aging. Routine use of advanced imaging modalities has increased the early detection of these tumors, and together with technological advances in radiotherapy planning and delivery techniques (stereotactic ablative body radiotherapy/radiosurgery) have made it possible effective radiation treatments with a relatively low toxicity profile in the primary tumor and selected cases of metastatic setting.
Nevertheless, robot-assisted surgery has allowed numerous potential benefits to the patients, reduced hospital stay and minor risk of infection and postoperative complications than conventional surgery.
The real-time molecular characterization of cancer disease, with the advent of potentially curative target therapies, has also becoming crucial to optimize a patient-tailored therapeutic approach based on tumor aggressiveness and clonal evolution.
In this scenario, a multidisciplinary team approach including all the specialties involved in the diagnostic and therapeutic procedures represents the key to offer personalized treatment plans and quality cancer care.
Recent advances in the diagnosis and treatment of prostate, bladder and kidney cancers, even in the setting of oligorecurrent/oligometastatic disease, have led to a growing evidence of improved control of disease and survival, which needs to also focus on treatment-related quality of life.
Given the current trend towards the hyperspecialized combination of diagnostics and therapeutics, both molecular and clinical data are desirable. We propose to create a multidisciplinary collector of scientific evidence that strengthen communication and synergy among the disciplines involved in an Uro-oncology molecular tumor board (Urology, Radiation Oncology, Clinical Oncology, Radiology, Nuclear Medicine, Pathology, Molecular Biology).
The Research Topic will cover technological advances in the field of prostate cancer, urothelial and renal tumors, regarding:
• next-generation imaging (multiparametric/whole body magnetic resonance, positron emission tomography, prostate cancer cell-ligands)
• the possible role of molecular biomarkers and/or genomic profiling
• surgical techniques
• radiation therapy, conventional chemotherapy and targeted therapy (monoclonal antibodies including PARP-inhibitors, immune modulation, androgen receptor signaling inhibitors)
• radiometabolic approaches
• efficacy and safety of combinatorial strategies
• advances in the management of treatment-related side effects (i.e. urinary incontinence/obstruction, radiation-induced proctitis, erectile disfunction, bladder shrinking, immune-related adverse events)
• features to evaluate and/or improve tumor detection and treatment response; treatment-related quality of life, patient-reported outcomes (PROs) and patient-reported outcome measures (PROMs); quality of care and cost-effectiveness of molecular tumor board.
Systematic and narrative reviews, metanalysis, prospective observational studies, retrospective series, subgroup analysis, real-world experiences, cost-effective analysis, clinical and pre-clinical data will be evaluated.